ResearcherJohannes Gutenberg University MainzActive in the last 2 years
Markus Hermann Moehler
Matched on OpenAlex author ID A5038131926. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 4
- Digital and AI-assisted multimodal supportive care, combining physical activity, nutrition, and pain management during chemotherapy for advanced pancreatic can… Last author DOI 10.1186/s12885-025-14867-6↗
- Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette s… Co-author DOI 10.1186/s12885-019-5889-5↗
- Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Co-author DOI 10.1038/bjc.2012.18↗
- Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III s… Co-author DOI 10.1186/1471-2407-11-346↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Cindy Neuzillet · 1 shared paper, 2025 · strength 0.16
- Barlo Hillen · 1 shared paper, 2025 · strength 0.16
- Irit Ben‐Aharon · 1 shared paper, 2025 · strength 0.16
- Francesco Sclafani · 1 shared paper, 2025 · strength 0.16
- Eva Ester Molina Beltran · 1 shared paper, 2025 · strength 0.16
- Hauke Lang · 2 shared papers, 2011–2019 · strength 0.12
- Paper Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: … DOI 10.1186/s12885-019-5889-5↗
- Paper Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic canc… DOI 10.1186/1471-2407-11-346↗
- Stefan Heinrich · 2 shared papers, 2011–2019 · strength 0.12
- Paper Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: … DOI 10.1186/s12885-019-5889-5↗
- Paper Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic canc… DOI 10.1186/1471-2407-11-346↗
- Mickaël Lesurtel · 2 shared papers, 2011–2019 · strength 0.12
- Paper Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: … DOI 10.1186/s12885-019-5889-5↗
- Paper Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic canc… DOI 10.1186/1471-2407-11-346↗
- Jean‐Luc Van Laethem · 1 shared paper, 2019 · strength 0.09
- Manfred Paul Lutz · 1 shared paper, 2019 · strength 0.09
- Marc G. Besselink · 1 shared paper, 2019 · strength 0.09
- Michel Pierre Ducreux · 1 shared paper, 2019 · strength 0.09
- Jan Harder · 1 shared paper, 2012 · strength 0.03
- Ralf‐Dieter Hofheinz · 1 shared paper, 2012 · strength 0.03
- Christoph Röcken · 1 shared paper, 2012 · strength 0.03
- Michael Geißler · 1 shared paper, 2012 · strength 0.03
- Volker Heinemann · 1 shared paper, 2012 · strength 0.03
- Anke Reinacher‐Schick · 1 shared paper, 2012 · strength 0.03
- Stefan Hubert Boeck · 1 shared paper, 2012 · strength 0.03
- Esther Endlicher · 1 shared paper, 2012 · strength 0.03
- Jean‐Robert Delpéro · 1 shared paper, 2011 · strength 0.02
- Frederik Christiaan Berrevoet · 1 shared paper, 2011 · strength 0.02
- Pierre‐Alain Clavien · 1 shared paper, 2011 · strength 0.02
- Philippe Bachellier · 1 shared paper, 2011 · strength 0.02
- Patrick Dufour · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.